Guangdong HEC Pharma publishes 2025 annual report

PUBT·04/30/2026 08:36:28

Listen to the news

Guangdong HEC Pharma annual report for year ended Dec. 31, 2025 outlined a return to profit, driven by a sharp rebound in influenza demand for core antiviral oseltamivir franchise.
Hong Kong listing on Aug. 7, 2025 marked shift toward innovative, vertically integrated model spanning R&D, manufacturing, commercialization.
Hepatitis C portfolio expanded with China market launches of Netanasvir Phosphate capsules, Encofosbuvir tablets in Feb.-Mar. 2025, positioned as an oral pan-genotype regimen with domestic IP.
Diabetes business scaled via insulin portfolio rollout, supported by centralized procurement wins, while US biologics license application for insulin glargine advanced through FDA site inspection in Sep.-Oct. 2025.
Pipeline momentum continued with first-time China clinical clearances for obesity candidates HEC-007, HEC-301 in 2025, followed by FDA clinical trial clearance for HEC-007 injection in Feb. 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260430-12138252), on April 30, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English